178 F. Supp. 3d 867
N.D. Cal.2016Background
- Plaintiff Kathie Sonner bought Joint Juice (contains 1,500 mg glucosamine, 200 mg chondroitin per serving) alleging Premier marketed it to relieve joint pain/stiffness and provide joint-health benefits, but the ingredients are ineffective or not bioavailable.
- Premier’s packaging and ads include statements like “helps keep cartilage lubricated and flexible,” athletic imagery, endorsements (Joe Montana, Arthritis Foundation logo), and a back-of-package FDA disclaimer that it is not intended to treat disease.
- Premier’s internal marketing research targeted consumers with joint pain; multiple Premier-commissioned surveys show large percentages of purchasers reported joint pain and bought the product for pain/health reasons.
- Scientific record disputed: plaintiff’s experts rely on meta-analyses, RCTs (including GAIT series), and bioavailability studies concluding little or no clinical benefit and minimal bioavailability; defendant’s expert cites some animal/in vitro studies and selective trials supporting efficacy.
- Procedurally: Premier moved for summary judgment and to exclude certain expert testimony; Sonner sought to exclude other defense experts and submitted errata to an expert deposition; court addressed admissibility issues and whether triable issues remain on UCL/CLRA claims.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether Premier’s packaging/ads convey an implied claim that Joint Juice relieves OA pain/stiffness | Sonner: marketing, imagery, endorsements, and Premier’s surveys show consumers reasonably infer palliative/structural benefits for arthritic joints | Premier: statements are general joint-health claims; disclaimer and absence of direct consumer-survey proof of implied message preclude liability | Triable factual dispute exists; Premier’s surveys and internal docs permit reasonable inference of implied message — summary judgment denied |
| Whether express claims (keep joints "lubricated and flexible") are false/misleading given scientific evidence | Sonner: meta-analyses, RCTs, guidelines, and bioavailability studies show no clinically meaningful benefit; experts say ingested compounds aren’t bioavailable at effective levels | Premier: scientific literature is equivocal; some studies support benefit; plaintiff’s claims are effectively a lack-of-substantiation claim not cognizable by private plaintiff | Jury issues remain because plaintiff presented admissible expert critique and studies; conflicting expert evidence means summary judgment inappropriate |
| Admissibility of expert testimony (Graboff, Grande, Poret, Willis errata) | Sonner: exclude Grande and Poret for flawed methods; defend Graboff/Willis | Premier: exclude Graboff (outside expertise) and strike Willis errata as sham; defend Grande and Poret | Graboff may testify on clinical practice/guidelines but not on bioavailability/scientific literature; Grande and Poret largely admissible with some opinion limitations; three Willis errata that contradict deposition stricken, two clarifying edits allowed |
| Restitution (full refund) theory | Sonner: Joint Juice is essentially a liquid supplement purchased solely for purported joint-health benefits; if valueless for that purpose, full refund appropriate | Premier: full-refund inappropriate absent proof product conferred no value; plaintiffs in other cases failed on full-refund theory | Court: triable issues on whether consumers bought solely for joint-health benefits and whether product had value; restitution theory survives summary-judgment stage |
Key Cases Cited
- Celotex Corp. v. Catrett, 477 U.S. 317 (summary judgment burden allocation)
- Anderson v. Liberty Lobby, 477 U.S. 242 (genuine issue for trial standard and view-evidence-in-light-most-favorable rule)
- Daubert v. Merrell Dow Pharm., 509 U.S. 579 (expert admissibility standard)
- Kumho Tire Co. v. Carmichael, 526 U.S. 137 (Daubert gatekeeping applies to non-scientific experts)
- Williams v. Gerber Prods. Co., 552 F.3d 934 (9th Cir.) (reasonable consumer test; cannot expect consumer to look beyond misleading front-package statements)
- Hambleton Bros. Lumber Co. v. Balkin Enters., Inc., 397 F.3d 1217 (9th Cir.) (limits on Rule 30(e) errata; sham corrections doctrine)